INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 20, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (NASDAQ: ITCI) regarding possible violations of federal securities laws from August 12, 2014 through April 28, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint states that, throughout the Class Period, Intra-Cellular made false and/or misleading statements and/or failed to disclose: that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; that these findings posed an additional safety concern regarding lumateperone; and that, as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.

On August 4, 2016, Intra-Cellular’s Chief Executive Officer, Sharon Mates, touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long-term exposure of ITI-007 to patients. After this information was released, Intra-Cellular’s stock price decreased materially, which harmed investors according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 466306